What’s Shaping Managed Care Pharmacy Now
Initiatives & Policy
AI can improve outcomes and efficiency, but payers need clear standards to ensure reliability, transparency, and equity. AMCP has launched initiatives focused on standards and best practices for AI, creating education, and fostering partnerships to guide responsible AI adoption.
Despite clinical guidelines, biomarker testing is unevenly applied, leaving patients without access to targeted therapies. AMCP is engaging payers and providers to align coverage with best practices, expand real-world evidence, and reduce gaps in precision medicine adoption.
RWE has enormous potential, but payers need consistent standards to evaluate quality and reduce bias.
AMCP is building frameworks, education, and multi-stakeholder collaboration to increase confidence and consistency in RWE use.
Metabolic diseases drive rising costs and disparities, yet evidence‑based care remains inconsistent. AMCP is advancing guidance, education, and collaboration to support aligned coverage, equitable access, and improved outcomes.
Patient perspectives are essential but often undervalued in formulary and coverage decisions. AMCP is clarifying the role of PED, educating payers, and creating tools to integrate it into decision-making, advancing more transparent and patient-centered care.
Across America, AMCP is monitoring and advocating for a range of health care issues and policies. Our mission is to improve medication access, elevate patient health outcomes, and optimize health care spending through evidence-based medication strategies. Learn about the priority issues we’re currently advocating for.
Featured Market Insights
More Marketing Insights Resources
To discuss managed care approaches to bsAbs with a focus on FL and DLBCL, AMCP Market Insights virtually convened an expert panel of managed care stakeholders in April 2025.
In September 2024, AMCP and Impact Education, LLC, held a virtual Market Insights summit with chief medical and pharmacy officers and other senior health care executives to discuss the management of retinal diseases in patients with diabetes.
Idiopathic hypersomnia (IH) is a chronic, neurologic disorder with a primary symptom of excessive daytime sleepiness
Featured Resources
More Resources